Suzanne Schindler and Charlotte Teunissen highlight discussions at CTAD 2024 on inclusive screening in clinical trials, use of blood-based biomarkers for diagnosis, and patient eligibility and dosing when using anti-amyloid therapies.
14-08-2024 | Alzheimer's Disease | Panel Discussion | Article | Supported by: Lilly